GT Biopharma (NASDAQ:GTBP) Stock Price Down 3.3% – What’s Next?

GT Biopharma, Inc. (NASDAQ:GTBP) shares traded down 3.3% during mid-day trading on Thursday . The stock traded as low as $0.64 and last traded at $0.65. 988,510 shares were traded during trading, a decline of 35% from the average session volume of 1,530,595 shares. The stock had previously closed at $0.6725.

Wall Street Analyst Weigh In

GTBP has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of GT Biopharma in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of GT Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, September 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, GT Biopharma presently has a consensus rating of “Sell”.

GT Biopharma Price Performance

The business’s fifty day moving average price is $0.70 and its 200 day moving average price is $1.48. The stock has a market cap of $6.92 million, a P/E ratio of -0.19 and a beta of 1.52.

GT Biopharma (NASDAQ:GTBP) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.45). On average, analysts predict that GT Biopharma, Inc. will post -6.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in GT Biopharma stock. Bank of Montreal Can boosted its holdings in shares of GT Biopharma, Inc. (NASDAQ:GTBP) by 531.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 92,530 shares of the company’s stock after acquiring an additional 77,879 shares during the quarter. Bank of Montreal Can owned 2.83% of GT Biopharma worth $331,000 at the end of the most recent quarter. 8.15% of the stock is currently owned by institutional investors.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.